Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Precision BioSciences, Inc.NASDAQ: DTIL

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $10.84M rose 37272.4% year over year, ahead of the -11.9% change in trailing-twelve-month revenue. Sequentially, it fell 68.3% from the prior quarter. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $11.35M (-66.9%) for the fiscal year ending Dec 2026, a slowdown from the -50.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.84M-68.3% QoQ
Last fiscal yearDec 2025
$34.26M-50.1% YoY
LTMMar 2026
$45.07M-11.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37272.4%+4011.1%-33261.3 pp
1 year-50.1%-66.9%-16.8 pp
3-year CAGR+10.9%-20.0%-30.9 pp
5-year CAGR+33.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
34.26M USD
Year-over-year change
-50.1%
4-year CAGR
-26.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 revenue of $45.07M is the 4th highest of the 7 companies compared; the peer median is $36.18M.
  • Its year-over-year change of -11.9% is the 2nd highest of 4, against a peer median of -55.4%.
  • Over three fiscal years its annual growth of +10.9% compares with a peer median of +12.9%.
DTIL Competitors Peer median
Revenue for DTIL and competitors
Company Period LTM YoY 3-year CAGR
HRTXHeron Therapeutics, Inc.LTM Mar 2026$150.71M +1.5%+12.9%
GOSSGossamer Bio, Inc.LTM Mar 2026$55.54M -55.4%—
QTTBQ32 Bio Inc.LTM Mar 2026$53.74M —+100.7%
DTILPrecision BioSciences, Inc.LTM Mar 2026$45.07M -11.9%+10.9%
RNAAtrium Therapeutics, Inc.FY2025$18.62M ——
ALECAlector, Inc.LTM Mar 2026$18.42M -79.2%-46.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 ——
Peer median (excluding DTIL) $36.18M-55.4%+12.9%

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue115.53M25.1M48.73M68.7M34.26M
Cost of Revenue00002.75M
Gross Profit115.53M25.1M48.73M68.7M31.51M
Gross Margin100.0%100.0%100.0%100.0%92.0%
Research & Development115.24M46.12M53.38M59.56M54.17M
Selling, General & Admin39.67M41.28M39.09M35.3M32.24M
Operating Expenses154.91M87.41M92.46M94.86M83.66M
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
EBITDA(20.27M)(62.79M)(32.04M)13.53M(42.43M)
EBITDA Margin-17.5%-250.2%-65.8%19.7%-123.8%
Operating Income(39.38M)(62.31M)(43.74M)(26.16M)(52.15M)
Operating Margin-34.1%-248.3%-89.8%-38.1%-152.2%
Interest Income208K3.47M7.69M6.76M4.24M
Interest Expense132K1.11M2.23M1.78M1.42M
Other Income / Expenses8.77M(10.6M)1.21M33.33M5.54M
Income Before Tax(30.6M)(72.91M)(42.53M)7.17M(46.61M)
Pre-Tax Margin-26.5%-290.5%-87.3%10.4%-136.0%
Income Tax Expense00000
Net Income(30.6M)(111.64M)(61.32M)7.17M(46.61M)
Net Margin-26.5%-444.8%-125.8%10.4%-136.0%
EPS (Basic)(15.60)(38.10)(15.96)1.05(3.63)
EPS (Diluted)(15.60)(38.10)(15.96)1.04(3.63)
Weighted Avg Shares1.96M2.93M3.84M6.83M12.83M
Weighted Avg Shares (Diluted)1.96M2.93M3.84M6.88M12.83M

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.